187 related articles for article (PubMed ID: 28273450)
1. ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.
Chen CF; Ruiz-Vega R; Vasudeva P; Espitia F; Krasieva TB; de Feraudy S; Tromberg BJ; Huang S; Garner CP; Wu J; Hoon DS; Ganesan AK
Cell Rep; 2017 Mar; 18(10):2331-2342. PubMed ID: 28273450
[TBL] [Abstract][Full Text] [Related]
2. Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.
Deichmann M; Thome M; Benner A; Kirschner M; Hassanzadeh J; Kurzen H
BMC Cancer; 2005 Jun; 5():58. PubMed ID: 15935100
[TBL] [Abstract][Full Text] [Related]
3. Knockout of MDA-9/Syntenin (SDCBP) expression in the microenvironment dampens tumor-supporting inflammation and inhibits melanoma metastasis.
Das SK; Guo C; Pradhan AK; Bhoopathi P; Talukdar S; Shen XN; Emdad L; Subler MA; Windle JJ; Sarkar D; Wang XY; Fisher PB
Oncotarget; 2016 Jul; 7(30):46848-46861. PubMed ID: 27341128
[TBL] [Abstract][Full Text] [Related]
4. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
5. β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.
Nsengimana J; Laye J; Filia A; O'Shea S; Muralidhar S; Poźniak J; Droop A; Chan M; Walker C; Parkinson L; Gascoyne J; Mell T; Polso M; Jewell R; Randerson-Moor J; Cook GP; Bishop DT; Newton-Bishop J
J Clin Invest; 2018 May; 128(5):2048-2063. PubMed ID: 29664013
[TBL] [Abstract][Full Text] [Related]
6. Mutations of the BRAF gene in benign and malignant melanocytic lesions.
Yazdi AS; Palmedo G; Flaig MJ; Puchta U; Reckwerth A; Rütten A; Mentzel T; Hügel H; Hantschke M; Schmid-Wendtner MH; Kutzner H; Sander CA
J Invest Dermatol; 2003 Nov; 121(5):1160-2. PubMed ID: 14708620
[TBL] [Abstract][Full Text] [Related]
7. Genetic similarities between Spitz nevus and Spitzoid melanoma in children.
Gill M; Cohen J; Renwick N; Mones JM; Silvers DN; Celebi JT
Cancer; 2004 Dec; 101(11):2636-40. PubMed ID: 15503312
[TBL] [Abstract][Full Text] [Related]
8. The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.
Deichmann M; Krahl D; Thome M; Wüst K; Hassanzadeh J; Helmke B
Int J Oncol; 2006 Jul; 29(1):139-45. PubMed ID: 16773193
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.
Jönsson G; Busch C; Knappskog S; Geisler J; Miletic H; Ringnér M; Lillehaug JR; Borg A; Lønning PE
Clin Cancer Res; 2010 Jul; 16(13):3356-67. PubMed ID: 20460471
[TBL] [Abstract][Full Text] [Related]
10. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction.
Turner DJ; Zirvi MA; Barany F; Elenitsas R; Seykora J
J Cutan Pathol; 2005 May; 32(5):334-9. PubMed ID: 15811117
[TBL] [Abstract][Full Text] [Related]
11. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
12. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
13. Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF.
Christensen C; Guldberg P
Oncogene; 2005 Sep; 24(41):6292-302. PubMed ID: 16007203
[TBL] [Abstract][Full Text] [Related]
14. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma.
Thomas NE; Edmiston SN; Alexander A; Millikan RC; Groben PA; Hao H; Tolbert D; Berwick M; Busam K; Begg CB; Mattingly D; Ollila DW; Tse CK; Hummer A; Lee-Taylor J; Conway K
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):991-7. PubMed ID: 17507627
[TBL] [Abstract][Full Text] [Related]
15. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
16. Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression?
Woenckhaus C; Giebel J; Failing K; Fenic I; Dittberner T; Poetsch M
J Pathol; 2003 Oct; 201(2):278-87. PubMed ID: 14517845
[TBL] [Abstract][Full Text] [Related]
17. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
18. [Role of tumor microenvironment in the formation and progression of skin melanoma].
Olbryt M
Postepy Hig Med Dosw (Online); 2013 May; 67():413-32. PubMed ID: 23756376
[TBL] [Abstract][Full Text] [Related]
19. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of BRAF mutations in localized cutaneous melanoma.
Nagore E; Requena C; Traves V; Guillen C; Hayward NK; Whiteman DC; Hacker E
J Am Acad Dermatol; 2014 May; 70(5):858-62.e1-2. PubMed ID: 24388723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]